Nsclc Panel

What is NSCLC PANEL test?

NSCLC stands for Non-Small Cell Lung Cancer, which is the most prevalent type of lung cancer in India. NSCLC panel is an NGS based test which offers complete genotyping solutions by amazing 13 genes relevant to lung cancer. It typically covers EGFR, ALK, ROS1, BRAF, MET, RET, ERBB2/HER2, KRAS and NTRK1/2/3, alongside other actionable or resistance‑associated genes, using NGS to report SNVs, INDELs, CNVs, and fusions from tumor tissue.

We also offer complementary report of EGFR by Real Time PCR, ALK by IHC and ROS1 by IHC in case of DNA or RNA failure during the NGS run.

Why consider NSCLC PANEL test?

Clinicians should consider & recommend NSCLC Panel for-

• Comprehensive therapy guidance as it assesses relevant 13 genes related to NSCLC to match patients to approved targeted therapies and trials.
• Consolidates multiple single‑gene tests into one assay, conserving limited tissue and shortening time to a clinically actionable, tumor‑board‑ready report.
• Detects resistance mutations at progression and samples tumor heterogeneity more effectively than sequential testing, supporting dynamic treatment adaptation.

Who should get this NSCLC PANEL test?

Clinicians should consider & recommend NSCLC Panel for-

• Newly diagnosed stage III/IV NSCLC (and squamous with clinical features suggesting a driver, such as younger age or minimal smoking) where broad, upfront testing can match to targeted therapies or trials.
• Cases with limited tissue or when rapid results are crucial, where a single panel conserves sample and shortens time to an actionable, tumor‑board‑ready report.
• Patients progressing on targeted therapy who need resistance profiling (e.g., EGFR, ALK, ROS1, MET mechanisms) to guide the next line of treatment.
• Individuals considered for immunotherapy or combination strategies, where panel results help contextualize choices alongside PD‑L1 and clinical factors.

 

More Information about NSCLC PANEL test

NSCLC stands for non-small cell lung cancer, the most common category of lung cancer that includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, and is managed with combinations of surgery, radiation, chemotherapy, targeted therapy, and immunotherapy based on stage and biomarkers. NSCLC (non-small cell lung cancer) is the most common type of lung cancer, making up about 80% of all lung cancer cases. It is a broad term for several types of epithelial lung cancers, with the main subtypes being adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. 

Other names: NSCLC panel; NSCLC test, Lung cancer targeted panel; NSCLC comprehensive genomic profiling (CGP) panel; Lung cancer panel, Lung cancer profiler next, Lung cancer NGS panel, Lung cancer 13 gene panel